Pharmaceutical Royalty Monetization / Life Sciences Financing
Strategic Profile
The company provides differentiated exposure to the fast-growing pharmaceutical and biotechnology industries through ownership and acquisition of royalties on pharmaceutical products, with a focus on delivering attractive growth in cash receipts from royalty assets over the long term. DRI Healthcare Trust is a global leader in providing financing to advance innovation in the life sciences industry.
Cyborg Score Rationale
In 2024 the Trust showed significant earnings growth compared to the previous year and advanced its investment strategy. The company has US$631.6 million of debt capacity with strong support from a syndicate of top-tier lenders. However, DHT.U underperformed the Canadian Market which returned 17.2% over the past year.
Top Insights
Since its initial public offering in 2021, the Trust has deployed more than $1.0 billion, acquiring more than 25 royalties on 20-plus drugs.
At December 31, 2024, the intangible royalty asset portfolio generated Total Cash Royalty Receipts of $190.0 million for the year and royalty income of $184.7 million.
As part of a November 2024 credit facility amendment, the interest rate on drawings was reduced by 0.25% and the maturity date was extended to November 1, 2027.
The portfolio includes royalties on blockbuster drugs including Eylea, Spinraza, Zytiga, Remicade, Keytruda, Stelara, and Xenpozyme.
Named Competitors
Royalty Income Trust — Global leader in pharmaceutical royalty acquisition and monetization
Biopharma Investment Fund — Diversified healthcare and pharmaceutical investment vehicle
Recent Developments
(March 2025) Announced 2024 full-year results with significant earnings growth and intangible royalty asset portfolio of $823.9 million
(November 2024) Upsized US$631.6 million credit facilities with extended maturity to November 2027 and reduced interest rates